ClinicalTrials.gg

Program

divarasib

Also written as “Divarasib” and “GDC-6036”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms, led by Hoffmann-La Roche.

Furthest: phase 3, since Jun 5, 201713 company-led studies, 9 open or runningNext primary completion: Nov 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche139 open or runningphase 3since Jun 5, 2017Jun 5, 2017Nov 30, 2026phase 2 · NCT04302025
  • Named in Hoffmann-La Roche’s own pipeline as RG6330 divarasib, phase 3, as of Oct 22, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 5, 2017First study: phase 3 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03178552 · 1,000 enrolled · United States, Argentina, Australia and more
  2. Mar 6, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04302025 · 99 enrolled · United States
  3. Jun 24, 2020Phase 1 study in Carcinoma, Non-Small-Cell LungNCT04449874 · 498 enrolled · United States, Australia, Belgium and more
  4. Oct 11, 2020Phase 2 study in Solid TumorsNCT04589845 · 920 enrolled · United States, Australia, Belgium and more
  5. Jun 11, 2021Phase 1 study in Colorectal NeoplasmsNCT04929223 · 542 planned · United States, Australia, Canada and more
  6. Feb 21, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05789082 · 320 planned · United States, Argentina, Australia and more
  7. Jul 5, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06497556 · 338 enrolled · United States, Argentina, Australia and more
  8. Nov 5, 20242 phase 1 studies in Healthy ParticipantsNCT06677957, NCT06690138
  9. Dec 11, 2024Phase 1 study in Hepatic ImpairmentNCT06734208 · 31 enrolled · United States
  10. Jan 20, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06793215 · 600 planned · United States, Argentina, Australia and more
  11. Feb 14, 2025Phase 1 study in Healthy ParticipantsNCT06835465 · 18 enrolled · United States
  12. Apr 14, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07541170 · 400 planned · United States, Argentina, Belgium and more

Ahead

  1. Nov 30, 2026Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT04302025
  2. Jun 30, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT03178552
  3. Dec 31, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT04449874
  4. Nov 30, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06793215

TargetBeta

“An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, divarasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes, s…”NCIt, read by Claude
“An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36
opnurasibruleNovartisphase 35

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07541170Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more3RecruitingJan 31, 2032400
NCT06835465Healthy Participants · United States1CompletedMay 6, 202518
NCT06793215Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingNov 30, 2028600
NCT06734208Hepatic Impairment · United States1CompletedNov 27, 202531
NCT06690138Healthy Participants · United States1CompletedFeb 11, 202518
NCT06677957Healthy Participants · United States1CompletedDec 30, 202419
NCT06497556Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingMay 19, 2026338
NCT05789082Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more2RecruitingJan 29, 2032320
NCT04929223Colorectal Neoplasms · United States, Australia, Canada and more1RecruitingAug 31, 2030542
NCT04589845Solid Tumors · United States, Australia, Belgium and more2Active, not recruitingSep 25, 2032920
NCT04449874Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more1Active, not recruitingDec 31, 2027498
NCT04302025Carcinoma, Non-Small-Cell Lung · United States2Active, not recruitingNov 30, 202699
NCT03178552Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingJun 30, 20271,000

How it is read

Names in the registry

  • “Divarasib”, 12 entries
  • “GDC-6036”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.